Press Release|

SHL Medical enters the 'New Normal'

Newnormal Covid19 1200x630 (1)

Since January 2020, SHL Medical has been closely monitoring the global effect of the Coronavirus 2019 (COVID-19).

We took early measures to protect the health and safety of our staff and ensure the continuity of drug delivery products for our customers and end-users during the crisis. Due to our manufacturing and production hub location in Taiwan, with its worldbeating epidemic response, we were able to continue production of all our devices as normal and worked with both suppliers and freight agencies to ensure uninterrupted business over the last six months.

Now, SHL Medical is keeping a step ahead in the next phase of the challenge. As we face the ‘new normal’ across all our sites, which are all at various stages, we are implementing measures that look forward to an evolved way of working.

Our manufacturing was not impacted during the crisis, and in fact, rose substantially. This will not change. A testament to our ongoing internal assessment and constant vetting of all design, quality, and manufacturing systems is the updating of processes and procedures, such as those to be compliant with the new European Union Medical Device Regulation (EU MDR). Although subsequently, the EU extended the MDR deadline, SHL Medical was and remains, ahead of the game in preparation for the new regulations.

As always, we maintain continuous monitoring and ongoing risk assessment and work closely with suppliers and partners to ensure the production and delivery of products.

Our staff are all educated and informed on the existing risks and the needs for continued hygiene and physical distance practice. The period of working from home for many staff has seen positive benefits of rapidly becoming familiar with our new digital collaboration tools, rolled out globally just before the pandemic hitVideo conferencing and remote collaborative working have become second nature to our staff across sites.

Just as we acted early in the pandemic to protect our customers, business and staff, we are now well-prepared to move forward together into the new normal.

Please contact us with any further enquiries you may have on the above. 

About SHL Medical

As a world-leading solutions provider of advanced drug delivery systems, SHL Medical is the partner of choice for many leading pharma and biotech companies. Driven by our company purpose – Enabling Patients’ Independence – we offer patient-centric solutions for the design, development, and manufacturing of autoinjectors, pen injectors, as well as innovative specialty delivery systems for large-volume and high-viscosity formulations. We also offer final assembly, labeling, and packaging solutions for our drug delivery systems.  ​

In response to the rising trend in home therapy, SHL has increased developmental work in the digital healthcare sector to help improve the drug delivery ecosystem

Located across Switzerland, Taiwan, Sweden, and the US, our global team of experts collaborate seamlessly as one team in utilizing our comprehensive in-house manufacturing capabilities. Our solutions offer customization and optimization for each project while proactively weaving sustainability-driven measures into our designs and processes to contribute to a cleaner earth.​

For additional information, visit www.shl-medical.com

Media contact: info@shl-medical.com

Share:

Related News

SHL Medical, a world-leading solutions provider of advanced drug delivery systems such as autoinjectors, pen injectors, and innovative specialty delivery systems has announced a strategic partnership with Grand River Aseptic Manufacturing (GRAM), a highly regarded contract development and manufacturing organization (CDMO) specializing in sterile injectable biologics and scalable pharmaceutical manufacturing solutions tailored to diverse client needs.